SEC Comment Letter 0000000000-25-000829 to Vor Biopharma Inc. (VOR)

Vor Biopharma Inc.
Date: Jan. 27, 2025 · CIK: 0001817229 · Accession: 0000000000-25-000829

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-284380

Date

January 27, 2025

Author

Robert Ang

Form

UPLOAD

Company

Vor Biopharma Inc.

Letter

January 27, 2025 Robert Ang President and Chief Executive Officer Vor Biopharma Inc. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 Re:Vor Biopharma Inc. Registration Statement on Form S-3 Filed January 21, 2025 File No. 333-284380 Dear Robert Ang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Katie Kazem

Show Raw Text

January 27, 2025
Robert Ang
President and Chief Executive Officer
Vor Biopharma Inc.
100 Cambridgepark Drive, Suite 101
Cambridge, MA 02140
Re:Vor Biopharma Inc.
Registration Statement on Form S-3
Filed January 21, 2025
File No. 333-284380
Dear Robert Ang:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Katie Kazem

SecProbe.io